Integration of genomic technologies for accelerated cancer drug development

Mark Basik, Spyro Mousses, Jeffrey Trent

Research output: Contribution to journalArticle

Abstract

New technologies have greatly increased the scientist's ability to investigate complex molecular interactions that occur in cancer development and to identify genetic alterations and drug targets. However, these new capabilities have not accelerated drug development efforts; rather, they may be contributing to increased research and development costs because the large number of new drug targets discovered through genomics need to be investigated in great detail to characterize their putative functional involvement in the disease process. One solution to this bottleneck in functional analysis is the use of high-throughput technologies to produce efficient processes that can rapidly handle the large flood of information at every stage of disease. This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project.

Original languageEnglish (US)
Pages (from-to)580-593
Number of pages14
JournalBioTechniques
Volume35
Issue number3
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Technology
Pharmaceutical Preparations
Human Genome Project
Neoplasms
Functional analysis
Molecular interactions
Microarrays
Genomics
Transfection
Genes
Throughput
Tissue
Costs and Cost Analysis
DNA
Research
Costs

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Basik, M., Mousses, S., & Trent, J. (2003). Integration of genomic technologies for accelerated cancer drug development. BioTechniques, 35(3), 580-593.

Integration of genomic technologies for accelerated cancer drug development. / Basik, Mark; Mousses, Spyro; Trent, Jeffrey.

In: BioTechniques, Vol. 35, No. 3, 01.09.2003, p. 580-593.

Research output: Contribution to journalArticle

Basik, M, Mousses, S & Trent, J 2003, 'Integration of genomic technologies for accelerated cancer drug development', BioTechniques, vol. 35, no. 3, pp. 580-593.
Basik, Mark ; Mousses, Spyro ; Trent, Jeffrey. / Integration of genomic technologies for accelerated cancer drug development. In: BioTechniques. 2003 ; Vol. 35, No. 3. pp. 580-593.
@article{438839ed6c3c454791404c8f11e75867,
title = "Integration of genomic technologies for accelerated cancer drug development",
abstract = "New technologies have greatly increased the scientist's ability to investigate complex molecular interactions that occur in cancer development and to identify genetic alterations and drug targets. However, these new capabilities have not accelerated drug development efforts; rather, they may be contributing to increased research and development costs because the large number of new drug targets discovered through genomics need to be investigated in great detail to characterize their putative functional involvement in the disease process. One solution to this bottleneck in functional analysis is the use of high-throughput technologies to produce efficient processes that can rapidly handle the large flood of information at every stage of disease. This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project.",
author = "Mark Basik and Spyro Mousses and Jeffrey Trent",
year = "2003",
month = "9",
day = "1",
language = "English (US)",
volume = "35",
pages = "580--593",
journal = "BioTechniques",
issn = "0736-6205",
publisher = "Eaton Publishing Company",
number = "3",

}

TY - JOUR

T1 - Integration of genomic technologies for accelerated cancer drug development

AU - Basik, Mark

AU - Mousses, Spyro

AU - Trent, Jeffrey

PY - 2003/9/1

Y1 - 2003/9/1

N2 - New technologies have greatly increased the scientist's ability to investigate complex molecular interactions that occur in cancer development and to identify genetic alterations and drug targets. However, these new capabilities have not accelerated drug development efforts; rather, they may be contributing to increased research and development costs because the large number of new drug targets discovered through genomics need to be investigated in great detail to characterize their putative functional involvement in the disease process. One solution to this bottleneck in functional analysis is the use of high-throughput technologies to produce efficient processes that can rapidly handle the large flood of information at every stage of disease. This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project.

AB - New technologies have greatly increased the scientist's ability to investigate complex molecular interactions that occur in cancer development and to identify genetic alterations and drug targets. However, these new capabilities have not accelerated drug development efforts; rather, they may be contributing to increased research and development costs because the large number of new drug targets discovered through genomics need to be investigated in great detail to characterize their putative functional involvement in the disease process. One solution to this bottleneck in functional analysis is the use of high-throughput technologies to produce efficient processes that can rapidly handle the large flood of information at every stage of disease. This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project.

UR - http://www.scopus.com/inward/record.url?scp=0043192566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043192566&partnerID=8YFLogxK

M3 - Article

C2 - 14513563

AN - SCOPUS:0043192566

VL - 35

SP - 580

EP - 593

JO - BioTechniques

JF - BioTechniques

SN - 0736-6205

IS - 3

ER -